Laser Focus World is an industry bedrock—first published in 1965 and still going strong. We publish original articles about cutting-edge advances in lasers, optics, photonics, sensors, and quantum technologies, as well as test and measurement, and the shift currently underway to usher in the photonic integrated circuits, optical interconnects, and copackaged electronics and photonics to deliver the speed and efficiency essential for data centers of the future.

Our 80,000 qualified print subscribers—and 130,000 12-month engaged online audience—trust us to dive in and provide original journalism you won’t find elsewhere covering key emerging areas such as laser-driven inertial confinement fusion, lasers in space, integrated photonics, chipscale lasers, LiDAR, metasurfaces, high-energy laser weaponry, photonic crystals, and quantum computing/sensors/communications. We cover the innovations driving these markets.

Laser Focus World is part of Endeavor Business Media, a division of EndeavorB2B.

Laser Focus World Membership

Never miss any articles, videos, podcasts, or webinars by signing up for membership access to Laser Focus World online. You can manage your preferences all in one place—and provide our editorial team with your valued feedback.

Magazine Subscription

Can you subscribe to receive our print issue for free? Yes, you sure can!

Newsletter Subscription

Laser Focus World newsletter subscription is free to qualified professionals:

The Daily Beam

Showcases the newest content from Laser Focus World, including photonics- and optics-based applications, components, research, and trends. (Daily)

Product Watch

The latest in products within the photonics industry. (9x per year)

Bio & Life Sciences Product Watch

The latest in products within the biophotonics industry. (4x per year)

Laser Processing Product Watch

The latest in products within the laser processing industry. (3x per year)

Get Published!

If you’d like to write an article for us, reach out with a short pitch to Sally Cole Johnson: [email protected]. We love to hear from you.

Photonics Hot List

Laser Focus World produces a video newscast that gives a peek into what’s happening in the world of photonics.

Following the Photons: A Photonics Podcast

Following the Photons: A Photonics Podcast dives deep into the fascinating world of photonics. Our weekly episodes feature interviews and discussions with industry and research experts, providing valuable perspectives on the issues, technologies, and trends shaping the photonics community.

Editorial Advisory Board

  • Professor Andrea M. Armani, University of Southern California
  • Ruti Ben-Shlomi, Ph.D., LightSolver
  • James Butler, Ph.D., Hamamatsu
  • Natalie Fardian-Melamed, Ph.D., Columbia University
  • Justin Sigley, Ph.D., AmeriCOM
  • Professor Birgit Stiller, Max Planck Institute for the Science of Light, and Leibniz University of Hannover
  • Professor Stephen Sweeney, University of Glasgow
  • Mohan Wang, Ph.D., University of Oxford
  • Professor Xuchen Wang, Harbin Engineering University
  • Professor Stefan Witte, Delft University of Technology

Is Remission Possible for Pancreatic Stage IV Cancer?

Newport Beach, California, United States - 09-08-2022 (PR Distribution™) -

Few diseases strike greater fear in patients more than pancreatic cancer – it is one of the most lethal of all human maladies. 

 “Patients often ask if remission is possible for late-stage pancreatic cancer!” says Gregory DiRienzo, CEO of Integrative Cancer Centers of America (www.iccahelp.com). “With our response often a conditional yes, provided the patient can undergo Live Cell Tumor Profiling.”  

“So how does Live Cell Tumor Profiling have the potential to increase treatment outcomes by as high as 200%, when many conventional cancer therapies can’t,” asks DiRienzo.

“First, you must accept that all living cells have a lethal enemy – Superman has kryptonite, Nightwalkers have Dragonglass with most cancers having lethal enemies as well, typically lethal chemo’s,” says DiRienzo, “however, chemo that may kill one patient’s cancer, may not kill another’s -- even with the same diagnosis!”

Here are three examples:

  1. 2012 study of 68 colon cancer patients given “DNA targeted “therapy -- 1 of 68 patients responded favorably (1.5%).
  2. 2015 study of 27 Colon Cancer patients with the “target B-Raf mutation” – 1 of 27 patients responded favorably (4%). 
  3. 2015 study of 229 patients “Gene-Directed “vs. Physicians’ directed - time to progression:   2.3 vs 2.0 months, clearly showing “molecularly targeted agents outside their indications do not improve progression-free survival.”  

Recognizing these inherent weaknesses, Integrative Cancer Centers now offers a 7-day test that can significantly improve survival rates by analyzing that patient’s unique live cancer cells and assessing which drugs as vast as they may be, will illicit the greatest cell death for that patient, even before, during, or after first-line therapy.

“Testing cancer cells against potential drugs offer patients the opportunity to take charge of their cancers and identify those treatments that will most likely work, and; is particularly helpful in treating cancers that have been considered “untreatable,” such as pancreatic, advanced lung, and recurrent breast cancers, “ says DiRienzo, 

With over 12,500 Live Cell Tumor Profiles done to date, the below scans graphically show the favorable outcome this very metastatic cancer patient experienced after undergoing live cell tumor profiling at our affiliate cancer centers in South America in 2013. 

By the way, the patient is still very much alive. 

Media Contacts:

Company Name: ICCA
Full Name: Greg DiRienzo
Phone: 949 939 0050
Email Address: Send Email
Website: http://www.iccahelp.com

For the original news story, please visit https://www.prdistribution.com/news/is-remission-possible-for-pancreatic-stage-iv-cancer/9277852.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.